Instrument Inactif

Communiqués Codiak BioSciences

Actions

CDAK

US1920101060

Communiqués

29/03/23	Codiak BioSciences : Failure to Satisfy Listing Rule - Form 8-K	PU
29/03/23	CODIAK BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
27/03/23	CODIAK BIOSCIENCES, INC. : Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/03/23	Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process	AQ
28/11/22	Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference	AQ
10/11/22	Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting	AQ
03/11/22	CODIAK BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
03/11/22	Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress	AQ
12/10/22	Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses	AQ
05/10/22	Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages	AQ
14/09/22	CODIAK BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/09/22	Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants	AQ
12/09/22	Codiak Announces Proposed Public Offering of Common Stock and Warrants	AQ
30/08/22	CODIAK BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/08/22	Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring	AQ
04/08/22	Codiak BioSciences : Reports Second Quarter 2022 Financial Results and Operational Progress - Form 8-K	PU
04/08/22	CODIAK BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/08/22	Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress	AQ
03/08/22	Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences	AQ
11/07/22	Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022	AQ
05/07/22	CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine	AQ
30/06/22	Codiak BioSciences : Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™ - Form 8-K	PU
30/06/22	CODIAK BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
30/06/22	Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™	AQ
29/06/22	Codiak BioSciences : Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer - Form 8-K	PU